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Abstract There are indications that in persons of
older age, systolic blood pressure (SBP) is no longer
associated with mortality. This raises the question
whether the predictive value of SBP changes from
younger to older age groups. Analysis in the Rotterdam
Study, a population-based prospective cohort study
among 4,612 participants aged ≥55 years without pre-
vious cardiovascular disease and with a median follow-
up of 14.9 (interquartile range, 11.1–15.8) years. Within
four age groups (55–64, 65–74, 75–84, ≥85 years),
the predictive value of baseline SBP for mortality
was studied. From age 55 to ≥85 years, risk of all-
cause mortality associated with SBP ≥160 mmHg
decreased from HR 1.7 (95%CI 1.2–2.2) to HR 0.7
(95%CI 0.4–1.1), p for trend <0.001. For participants
with SBP 140–159 mmHg, the risk decreased from HR
1.2 (95%CI 0.9–1.5) to HR 0.7 (95%CI 0.5–1.1), p for
trend <0.001. Analyses in the 5-year age groups showed
an increased risk with higher SBPs up to age 75 years.
After 75 years, a trend towards SBP no longer being
associated with an increased mortality risk was seen in
our study. These findings need to be considered with
recently reported beneficial effects of antihypertensive
treatment in this age group.
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Introduction
High systolic blood pressure (SBP) is recognized as an
important risk factor for cardiovascular disease
(CVD), irrespective of age (Lewington et al. 2002).
However, observational cohort studies in older popu-
lations report that high SBP does not predict mortality
from age 75 years onwards (Alli et al. 1999; Van
Bemmel et al. 2006a, b; Boshuizen et al. 1998; Bulpitt
and Fletcher 1992; Guo et al. 1997; Hakala et al. 1997;
Heikinheimo et al. 1990; Kagiyama et al. 2008; Lernfelt
and Svanborg 2002; Molander et al. 2008; Oates et al.
2007; Okayama et al. 2006; Rajala et al. 1983; Rastas et
al. 2006; Satish et al. 2001a, b; Trenkwalder et al. 1999).
Therefore, the value of SBP to predict mortality may
change from younger to older age groups. As previous
studies were performed in cohorts of exclusively older
people, the age at which the association between SBP
and mortality starts to fade remains unknown and needs
to be studied in a large cohort with a wider age range.
The present study aims to determine the risk pre-
diction of all-cause and (non)cardiovascular mortality
with SBP in persons without a history of CVD across
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increasing age categories from age 55 years onwards.
As diastolic blood pressure (DBP) loses its predictive
abilities for mortality in adults aged over 50 years
(Taylor et al. 2011), only SBP is investigated in this
study.
Methods
Study population
Data for this study were derived from the Rotterdam
Study, a population-based prospective cohort study
including 7,983 participants (4,878 women and
3,105 men) aged 55 years and over, living in Ommoord
(an urban district of Rotterdam, the Netherlands). The
study has been described in detail elsewhere (Hofman et
al. 2009). The Medical Ethics Committee of the
Erasmus University Medical Center approved the
study and written informed consent was obtained
from all participants.
For the present study, we excluded all participants
with a history of CVD, defined as myocardial infarc-
tion, coronary interventions (percutaneous coronary
interventions or coronary artery bypass grafts), ische-
mic and hemorrhagic stroke, atrial fibrillation and
peripheral arterial disease (n02,294); an additional
308 participants were excluded because data on car-
diovascular history were missing. The prevalence of
prior CVD (overall 2,294/7,983; 29%), increased with
increasing age: 18% in age group 55–64 years, 29% in
age group 65–74 years, 49% in age group 75–84 years,
and 71% in patients aged ≥85 years. Of the 5,381
participants available for the present study blood
pressure data were available for 4,612 (85.7%) persons,
which was the final sample size.
Measurements
Between 1990 and 1993 participants visited the re-
search center for the baseline examination, at which
blood pressure measurements were obtained. Blood
samples were taken for measurement of total choles-
terol and high-density cholesterol, body mass index
was assessed, as well as participants’ history of smok-
ing and diabetes mellitus. Blood pressure measure-
ments were carried out by research assistants using a
standardized protocol. SBP (Korotkoff phase I)
was measured in duplicate on the right arm using a
random-zero sphygmomanometer (with a 14×38 cm
cuff), after the participant had been seated for at least
5 min. The mean of the two blood pressures values was
used in the analyses. For SBP, three categories for blood
pressure were used according to the European guide-
lines on CVD prevention in clinical practice (Mancia et
al. 2007), namely “normal” (SBP <140 mmHg), “grade
1 hypertension” (SBP 140–159 mmHg) or “grade 2
hypertension or higher” (SBP ≥160 mmHg) were used.
Data on the use of antihypertensive medication
(ATC codes: C02, C03, C07) were collected through
interviews. Medication containers were checked dur-
ing the interview. A SBP ≥160 mmHg was reported to
the participant’s general practitioner (GP), unless the
GP was already informed about the participant’s
hypertension.
Follow-up
In the Rotterdam Study, data on all-cause mortality are
obtained in two ways. Participants living independently
in the area of Ommoord are followed by continuous
monitoring of the municipal address files and are con-
sidered to have complete follow-up with respect to vital
status (i.e., they are still alive at the reference date).
Participants living outside Ommoord and/or in a nursing
home were at least alive at the last date of manual data
collection; these subjects have partial follow-up. The
completeness of follow-up is the ratio of the total
number of observed person-years and the total number
of potential person-years (Clark et al. 2002). Mean
intervals from baseline measurements until death varied
with age at baseline and were 14.4, 13.2, 10.1 and
5.6 years for the age groups 55–64, 65–74, 75–84
and ≥85 years, respectively.
Endpoints
A detailed description of the procedure to classify
events has been published earlier (Mattace-Raso et
al. 2004). All information on possible events was
obtained from the participant’s GP and subsequently
classified independently by two research physicians.
In case of disagreement, consensus was reached in a
plenary session. A medical expert in the field of CVD
verified all these events. This verification was consid-
ered definite. Classification of events was based on the
International Classification of Diseases, 10th revision
(ICD-10). Events followed by death within 28 days
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were classified as fatal. Cardiovascular mortality was
defined as mortality from coronary heart disease (ICD-
10 codes I20–I25, I46, I49, I50, I60–I67, I70–I74, and
R96) or stroke (ICD-10 codes I60–I67). Noncardio-
vascular mortality was defined as all other mortality,
other than cardiovascular mortality.
Data analysis
Differences in characteristics between participants in
the lowest, middle, and highest SBP groups were
tested with the chi-square test for categorical variables
and the Jonkheere–Terpstra tests for continuous varia-
bles.Within strata by age group (at baseline 55–64 years,
65–74, 75–84 and >85 years), risk estimates (hazard
ratios) were calculated for the relation between SBP at
baseline, and all-cause and (non)cardiovascular mortal-
ity, using a Cox proportional hazards model. Since the
aim was to determine the predictive value of SBP (as
opposed to exploring etiological pathways), results were
not adjusted for potential confounders, but for age (per
age category, as a continuous variable) and sex only. For
all participants, including those using antihypertensive
medication, the actual blood pressure is used in the
analysis. Analyses were repeated in strata according to
baseline use of antihypertensive medication.
Because of suggestions in the literature to use
150mmHg as a treatment target in older people (Beckett
et al. 2008), as sensitivity analysis we used categories of
blood pressure with a corresponding reference group:
“reference” (SBP <150 mmHg), SBP 150–159 mmHg
or SBP ≥160 mmHg. Additionally, to evaluate the in-
fluence of the arbitrarily chosen age groups, all analyses
were repeated in 5-year interval age groups (at baseline
55–59 years, 60–64, 65–69, 70–74, 75–79, 80–84,
and >85 years), as well as in 10-year interval age groups
(at baseline 55–59 years, 60–69, 70–79, and ≥80 years).
Analyses were performed using SPSS 16.0 forWindows
(SPSS, Chicago, IL, USA).
Results
Table 1 shows the baseline characteristics of the par-
ticipants, including other cardiovascular risk factors.
Mean age at baseline was 67.4 (range, 55.0–106.2)
years. The prevalence of increased SBP increased with
age.
Follow-up was completed until 1 January 2008 for
all-cause mortality and until 1 January 2005 for cause-
specific mortality (both complete for 99.0%). The
median duration of follow-up was 14.9 (interquartile
range (IQR) 11.1–15.8) years for all-cause mortality
and 12.1 (IQR 10.8–13.0) years for cause-specific
mortality. During follow-up, overall mortality in-
creased from 12.1/1,000 person-years (1.1% in the
first year of follow-up) in those aged 55–64 years to
168.1/1,000 person-years (13.0% in the first year of
follow-up) in those aged 85 years and over.
Risk of all-cause mortality
Relative risks adjusted for age and sex associated with
SBP ≥160 mmHg, compared to the reference group
SBP <140 mmHg, decreases with age from HR≥160
1.7 (95% CI: 1.2, 2.2) in the age group 55–64 years, to
HR≥160 0.7 (95%CI: 0.4, 1.1) in the age group ≥85 years
(p for trend <0.001; Table 2). For SBP ≥140–159mmHg
the same trend could be seen: HR140–159 1.2 (95% CI:
0.9, 1.5) in the age group 55–64 years, to HR140–159 0.7
(95% CI: 0.5, 1.1) in the age group ≥85 years (p for
trend <0.001).
When participants were categorized into 5-year age
groups, the increased risk with higher SBPs was pres-
ent up to age 75 years: in the age group 70–74 years,
the HR140–159 is 1.4 (95% CI: 1.1, 1.7) and in the age
group 75–79 years and over the HR reaches unity
(HR140–159 1.1, 95% CI: 0.9, 1.4). For the group with
the highest SBPs, in the age group 70–74 years, the
HR≥160 is 1.3 (95% CI: 1.0, 1.7). Relative risks in the
age group 75–79 and 80–84 years are similar, whereas
in the age group ≥85 years HR≥160 is 0.7 (95% CI: 0.4,
1.1). Using a reference group with SBP <150 mmHg
shows similar results with HR150–159 0.8 (95% CI: 0.5,
1.3) and HR≥160 0.8 (95% CI: 0.5, 1.2) at age ≥85 years
(data not shown).
Figure 1 shows absolute mortality, presented as all-
cause mortality rate (per 1,000 person-years) depend-
ing on two levels of SBP: <140 and ≥160 mmHg.
Between age 75 and 85 years, the absolute mortality
risk reverses, with SBP <140 mmHg being related to
higher mortality than SBP ≥160 mmHg.
Risk of cardiovascular mortality
In the age group 55–64 years, the risk of cardiovascu-
lar mortality was increased for participants with SBP
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≥160 mmHg (HR≥160 2.9, 95% CI: 1.4, 5.9) compared
to those with SBP <140 mmHg. In the higher age
groups, this risk decreases (at age ≥85 years: HR≥160
0.9, 95% CI: 0.3, 2.1). The same applies to the relative
risks associated with SBP 140–159 mmHg: HR140–159
2.1, 95% CI: 1.1, 3.9 for age 55–64 and HR140–159 1.3,
95% CI: 0.6, 2.8 for age ≥85 (p for trend <0.001;
Table 2).
Risk of noncardiovascular mortality
Noncardiovascular mortality is increased with a higher
SBP in the younger age groups, but in those aged 75–
84 years the relative risk reaches unity. For partici-
pants aged ≥85 years, the risk for noncardiovascular
mortality was decreased (HR140–159 0.6, 95% CI: 0.3,
1.0, and HR≥160 0.7, 95% CI: 0.4, 1.2) compared to
participants aged 55–64 years (HR140–159 1.0, 95% CI:
0.7, 1.4, and HR≥160 1.3, 95% CI: 0.9, 2.0), p for
trend00.001 (Table 2).
Additional analyses (data not shown)
When participants were stratified according to the use
of antihypertensive medication at baseline, results in
both strata were roughly similar. Excluding the partic-
ipants who died in the first year of follow-up (n054)
yielded similar results.
Discussion
This analysis in the Rotterdam Study shows that the
predictive value of SBP for mortality differs with age
in people aged 55 years and over without a history of
CVD. Between age 55 and 75 years, high SBP pre-
dicts higher mortality risk. From age 75 years on-
wards, we observed a significant trend indicating that
SBP no longer predicts increased mortality, although
due to lower numbers in the higher age-groups the
hazard ratios in each age group were not significant.
Table 1 Baseline characteristics of the participants (n04,612)
SBP (mmHg) p Value
<140 140–159 ≥160
n02,632 n01,288 n0692
Men, n (%) 1,022 (38.8) 489 (38.0) 243 (35.1) 0.090
Duration of follow-up in years 15.0 (12.7–16.0) 14.9 (10.1–15.6) 14.5 (8.9–15.3) <0.001
Age groups, n (%)
55–64 years 1,413 (68.0) 460 (22.1) 205 (9.9)
65–74 years 860 (51.1) 540 (32.1) 283 (16.8)
75–84 years 307 (43.1) 242 (33.9) 164 (23.0)
≥85 years 52 (37.7) 46 (33.3) 40 (29.0) <0.001
SBP in mmHg 124 (114–124) 148 (144–153) 171 (164–179) −
DBP in mmHg 69 (63–75) 77 (71–84) 85 (78–93) <0.001
Participants with antihypertensive medicationa n (%) 512 (19.5) 353 (27.4) 255 (36.8) <0.001
Other cardiovascular risk factors
HDL cholesterol in mmol/L 1.3 (1.1–1.6) 1.3 (1.1–1.6) 1.3 (1.1–1.6) 0.381
total cholesterol in mmol/L 6.5 (5.8–7.3) 6.6 (5.9–7.4) 6.7 (5.8–7.5) 0.003
Body mass index 25.5 (23.5–27.9) 26.3 (24.3–28.8) 26.6 (24.6–28.9) <0.001
Diabetes mellitus (%) 146 (5.5) 119 (9.2) 85 (12.3) <0.001
Smoking (%) 652 (24.8) 230 (17.9) 122 (17.6) <0.001
Continuous variables are presented as median with interquartile range
DBP diastolic blood pressure
a Antihypertensive medication defined as ATC codes C02, C03, and C07
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Table 2 All-cause and cause-specific mortality risks for participants without a history of cardiovascular disease (n04,612) by baseline
SBP categories, adjusted for age and sex
SBP (mmHg)
Eventsa ARb<140 <140 140–159 ≥160 p for trend
n02,632 n01,288 n0692
All-cause mortality
55–64 years 363 10.7 1 1.2 (0.9–1.5) 1.7 (1.2–2.2) <0.001
65–74 years 730 30.5 1 1.2 (1.0–1.4) 1.3 (1.0–1.5) 0.006
75–84 years 567 75.5 1 1.1 (0.9–1.3) 1.3 (1.0–1.6) 0.047
≥85 years 131 219.0 1 0.7 (0.5–1.1) 0.7 (0.4–1.1) 0.286
p for trend <0.001 <0.001
Cardiovascular mortality
55–64 years 53 1.4 1 2.1 (1.1–3.9) 2.9 (1.4–5.9) <0.001
65–74 years 118 5.6 1 1.3 (0.8–1.9) 1.2 (0.7–2.0) 0.059
75–84 years 119 17.8 1 0.9 (0.6–1.4) 1.3 (0.8–2.1) 0.142
≥85 years 39 51.1 1 1.3 (0.6–2.8) 0.9 (0.3–2.1) 0.626
p for trend <0.001 <0.001
Noncardiovascular mortality
55–64 years 214 8.1 1 1.0 (0.7–1.4) 1.3 (0.9–2.0) 0.193
65–74 years 403 29.4 1 1.2 (1.0–1.5) 1.3 (1.0–1.7) 0.063
75–84 years 337 49.6 1 1.0 (0.8–1.3) 1.2 (0.9–1.6) 0.369
≥85 years 92 176.6 1 0.6 (0.3–1.0) 0.7 (0.4–1.2) 0.425
p for trend <0.001 <0.001
a Numbers for all-cause mortality are higher than cause-specific mortality due to longer follow-up
bAR absolute risk (number of events/1,000 person-years)
all cause mortality and SBP
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From age 85 years onwards, high SBP even predicts
lower mortality risk, confirming earlier observations
in the oldest old (Van Bemmel et al. 2006a)
In 1992 a review of observational population studies
relating blood pressure to mortality in older persons, a
weaker association between SBP andmortality from age
75 years onwards was reported (Bulpitt and Fletcher
1992). Since then, several individual studies have
reported on the fading association between SBP and
mortality and cardiovascular morbidity in older persons
(Alli et al. 1999; Van Bemmel et al. 2006a, b; Boshuizen
et al. 1998; Heikinheimo et al. 1990; Molander et
al. 2008; Nelson et al. 2011; Okayama et al. 2006;
Satish et al. 2001b; Trenkwalder et al. 1999).
However, most of these studies had a relatively
heterogeneous population (age, previous CVD or
use of antihypertensive medication, high-risk pop-
ulations) and methodologies (measurement of
blood pressure, length of follow-up, and measure-
ment of outcomes). We are the first to show the
changing predictive value of SBP across the age
span within a single population-based cohort.
Our results only partly agree with a landmark meta-
analysis published in 2002, which included data from
one million adults without a history of CVD from 61
prospective studies, with age-specific relevance of
blood pressure as primary focus of attention (Lewington
et al. 2002). This meta-analysis demonstrated a progres-
sive slowing down with age of the rate of increase of
cardiovascular mortality and morbidity risks with in-
creasing SBPs, but did not show a reversal of risks in
their highest age group (80 years and over). Whether
inclusion of all recently published studies that used
cohorts of older people would alter these estimations
remains to be seen.
Our population-based study has several strengths.
The population studied is highly representative for
those without a history of CVD in the general popu-
lation, and therefore reflects the population that would
be addressed by systematic screening as a means of
primary prevention of CVD. A high response rate,
almost complete follow-up, and uniformity in method-
ology and data collection in all participants reinforce
internal validity and generalizability. In addition, our
study employs various strata of age groups, allowing
determination of the specific age at which the associa-
tion between SBP and mortality disappears and subse-
quently reverses. It may be seen as a weakness that
GPs were notified about previously unrecognized
hypertension, potentially causing misclassification.
Since in the younger age groups (≤75 years) robust
correlations of high SBP and increased mortality risk
were observed, and since it is likely that participants in
these age groups were treated more strictly than those in
older age groups, this almost certainly did not influence
our results (Di Bari et al. 1999). All our prognostic
analyses were based on a (twice repeated) blood pres-
sure measurement at one point in time, and not on a
series of blood pressure measurements over time. Al-
though the latter would have been interesting from an
etiological point of view, a single blood pressure esti-
mation is in keeping with current practice with regard to
cardiovascular risk prediction and the use of various risk
functions, such as the Framingham Risk Score and
SCORE (D’Agostino et al. 2001; Ezzati et al. 2002).
In view of the observational design of the data
collection, analyses with regard to the effect of anti-
hypertensive medication are bound to be confounded
by prescription bias. Therefore, we did not perform
analyses to study effect of medication. To understand
the possible clinical consequences of our findings, it is
important to combine our results with the recently
reported beneficial effects of antihypertensive treat-
ment of (relatively healthy) persons aged 80 years
and over (Beckett et al. 2008; Bejan-Angoulvant et
al. 2010). Thus, although high SBP does not predict
mortality above age 75 years, antihypertensive treat-
ment still has a beneficial outcome in these age
groups. Reductions in total mortality, incidence of
stroke, heart failure, and all cardiovascular events have
been shown (Beckett et al. 2008). This is not a unique
concept in the very old, since in this age group it has
also been shown that high total cholesterol levels are
associated with better survival than low cholesterol
levels (Weverling-Rijnsburger et al. 1997), while at
the same time statin treatment in older populations
has been proven beneficial (Shepherd et al. 2002).
To understand the apparent contradiction regarding
SBP, it is important to elucidate the etiology of the
change in prediction of negative clinical outcomes by
SBP in higher age groups. The population of people of
old age includes relatively many subjects with de-
creasing blood pressure, since SBP is known to de-
crease in the last years before dying (Satish et al.
2001a). Decreases in SBP as a sign of imminent
heart failure, could underlie the observed worse prog-
nosis in these individuals (van Bemmel et al. 2009).
Participants with formerly higher blood pressures, but
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now a decreasing blood pressure due to (imminent)
heart failure, cause the increased absolute risk of
mortality in the low blood pressure group. None-
theless, antihypertensive medication for those with
high blood pressure reduces this incidence of heart
failure (Beckett et al. 2008). Another explanation
for our findings could be that age becomes such a
strong risk factor with increasing age that it is
difficult for other risk factors to have an additional
prognostic effect. Some have therefore agued to
confine cardiovascular risk prediction to age-based pre-
diction alone (Wald et al. 2011). However, this still does
not explain the reversal of risk in those participants aged
85 and over.
Other important questions raised by this study are:
Is antihypertensive treatment beneficial for all older
subjects with high SBP, or should those with falling
blood pressure be identified? Who will not benefit
from antihypertensive treatment? Should antihyperten-
sive medication be lowered or discontinued in specific
subgroups of older patients?
In conclusion, the predictive value of SBP for mor-
tality differs with age in people aged 55 years and over
without a history of CVD. Between age 55 and 75 years,
high SBP predicts higher mortality risk, but from age
75 years onwards a significant trend shows that SBP
levels no longer predict mortality risk (although hazard
ratios per age group do not reach significance). From
age 85 years onwards, high SBP even predicts lower
mortality risk. The discrepancy of these predictive find-
ings together with recently shown beneficial effects of
antihypertensive treatment also in high age groups fuels
the necessary discussion about possible clinical conse-
quences. Future studies should use a longitudinal ap-
proach to explore how changing blood pressure is linked
to mortality risk.
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